Fewer than 10% of patients that would benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its inaugural guidance on the medications.
With over a billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable access to this class of drugs.
Based on projections, over two billion could be obese by 2030 if no action is taken.
"Our new guidelines recognises that obesity is a lifelong illness that can be managed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to widespread availability to the treatments that can aid individuals in losing substantial weight, says the organization.
Skinny Jab Supply Crisis
Even under the current most favorable scenario, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation calls on nations and manufacturers to increase availability, via measures like licensing agreements.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Drugs Operate
The injections mimick a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so people eat less.
Individuals usually start to lose weight within a few weeks of beginning the weekly injections.
Research suggests people may put most of the weight back on after a year of discontinuing the medication, because their normal food cravings return.
Being overweight or obese raises your risk for developing diseases, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.
